CDC28 protein kinase regulatory subunit 1B pseudogene 4Genealiases: []
Q-omics provides the consensus-scored CKS1BP4 profile across patient tissues and cancer cell-line models. CKS1BP4 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CKS1BP4 is differentially expressed in 3, with the highest sampling consensus in ESCA. Additionally, CKS1BP4 RNA expression shows 6,995 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, ESCA, and ACC as cancer lineages where CKS1BP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CKS1BP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CKS1BP4 survival associations across molecular data types. CKS1BP4 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CKS1BP4 RNA expression–survival associations across cancer types. High CKS1BP4 expression shows unfavorable associations in MESO, ACC and BLCA, but favorable associations in SKCM, HNSC and READ. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CKS1BP4 RNA expression.
This table summarizes CKS1BP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for CKS1BP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CKS1BP4 shows lower tumor expression in ESCA and higher tumor expression in KIRP and LUSC. The ESCA box plot shows higher CKS1BP4 RNA expression in normal versus tumor tissue (log2 FC = −0.270, t-test p = .001).
This table shows molecular features associated with CKS1BP4 in patient tissues and cancer cell lines. In patient samples, CKS1BP4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
